Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to evaluate the real-world efficacy of immune checkpoint inhibitors (ICIs), and to identify clinicolaboratory factors to predict treatment outcomes in patients with advanced esophageal squamous cell carcinoma (ESCC) receiving ICIs. Materials and methods: Sixty patients with metastatic or unresectable ESCC treated with nivolumab (n=48) or pembrolizumab (n=12) as ≥ second-line treatment between 2016 and 2019 at Asan Medical Center were included. Results: The median age of the patients was 68 years (range, 52 to 76 years), and 93.3% were male. Most patients had metastatic disease (81.7%) and had been previously treated with fluoropyrimidines, platinum, and taxane. In 53 patients with measurable disease, the overall response rate and disease control rate were 15.1% and 35.8%, respectively. With a median follow-up duration of 16.0 months, the median progression-free survival (PFS) and overall survival (OS) were 1.9 months (95% confidence interval [CI], 1.54 to 2.19) and 6.4 months (95% CI, 4.77 to 8.11), respectively. After multivariate analysis, recent use of antibiotics, low prognostic nutrition index (< 35.93), high Glasgow Prognosis Score (≥ 1) at baseline, and ≥ 1.4-fold increase in neutrophil-to-lymphocyte ratio after one cycle from baseline were significantly unfavorable factors for both PFS and OS. Younger age (< 65 years) was a significant factor for unfavorable PFS and hyponatremia (< 135 mmol/L) for unfavorable OS. Conclusion: The use of ICIs after the failure of chemotherapy showed comparable efficacy in patients with advanced ESCC in real practice; this may be associated with host immune-nutritional status, which could be predicted by clinical and routine laboratory factors.
Abstract
Purpose: This study aimed to evaluate the real-world efficacy of immune checkpoint inhibitors (ICIs), and to identify clinicolaboratory factors to predict treatment outcomes in patients with advanced esophageal squamous cell carcinoma (ESCC) receiving ICIs. Materials and methods: Sixty patients with metastatic or unresectable ESCC treated with nivolumab (n=48) or pembrolizumab (n=12) as ≥ second-line treatment between 2016 and 2019 at Asan Medical Center were included. Results: The median age of the patients was 68 years (range, 52 to 76 years), and 93.3% were male. Most patients had metastatic disease (81.7%) and had been previously treated with fluoropyrimidines, platinum, and taxane. In 53 patients with measurable disease, the overall response rate and disease control rate were 15.1% and 35.8%, respectively. With a median follow-up duration of 16.0 months, the median progression-free survival (PFS) and overall survival (OS) were 1.9 months (95% confidence interval [CI], 1.54 to 2.19) and 6.4 months (95% CI, 4.77 to 8.11), respectively. After multivariate analysis, recent use of antibiotics, low prognostic nutrition index (< 35.93), high Glasgow Prognosis Score (≥ 1) at baseline, and ≥ 1.4-fold increase in neutrophil-to-lymphocyte ratio after one cycle from baseline were significantly unfavorable factors for both PFS and OS. Younger age (< 65 years) was a significant factor for unfavorable PFS and hyponatremia (< 135 mmol/L) for unfavorable OS. Conclusion: The use of ICIs after the failure of chemotherapy showed comparable efficacy in patients with advanced ESCC in real practice; this may be associated with host immune-nutritional status, which could be predicted by clinical and routine laboratory factors.
참고문헌 (30)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016", Cancer Research and Treatment, 51(2), pp.417~430 (2019), 대한암학회
- Shin A, "Trends in incidence and survival of esophageal cancer in Korea : analysis of the Korea Central Cancer Registry Database", J Gastroenterol Hepatol, 33, pp.1961~1968 (2018)
- Al-Batran SE, "Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin : a study of the Arbeitsgemeinschaft Internistische Onkologie", J Clin Oncol, 26, pp.1435~1442 (2008)
- Ford HE, "Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma(COUGAR-02) : an open-label, phase 3 randomised controlled trial", Lancet Oncol, 15, pp.78~86 (2014)
- Thuss-Patience PC, "Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer : a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie(AIO)", Eur J Cancer, 47, pp.2306~2314 (2011)
- Doi T, "Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma", J Clin Oncol, 36, pp.61~67 (2018)
- Shah MA, "Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esop-hagus : the phase 2 KEYNOTE-180 study", JAMA Oncol, 5, pp.546~550 (2019)
- Kudo T, "Nivolumab treatment for oesophageal squamous-cell carcinoma : an open-label, multicentre, phase 2 trial", Lancet Oncol, 18, pp.631~639 (2017)
- Kojima T, "Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer : phase III KEYNOTE-181 study", J Clin Oncol, 37, pp.2~ (2019)[DOI]
- Kato K, "Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy(ATTRACTION-3) : a multicentre, randomised, open-label, phase 3 trial", Lancet Oncol, 20, pp.1506~1517 (2019)
- Hall PS, "Optimizing chemotherapy for frail and elderly patients(pts)with advanced gastroesophageal cancer(aGOAC) : the GO2 phase III trial", J Clin Oncol, 37(15 Suppl), pp.4006~ (2019)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Chen MF, "The predictive value of pretreatment neutrophil-to-lymphocyte ratio in esophageal squamous cell carcinoma", Ann Surg Oncol, 26, pp.190~199 (2019)
- Onodera T, "Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients", Nihon Geka Gakkai Zasshi, 85, pp.1001~1005 (1984)
- Wang Y, "The prognostic value of pretreatment Glasgow Prognostic Score in patients with esophageal cancer : a meta-analysis", Cancer Manag Res, 11, pp.8181~8190 (2019)
- Feng JF, "Gustave Roussy Immune Score(GRIm-Score)is a prognostic marker in patients with resectable esophageal squamous cell carcinoma", J Cancer, 11, pp.1334~1340 (2020)
- Mezquita L, "Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in pati-ents with advanced non-small cell lung cancer", JAMA Oncol, 4, pp.351~357 (2018)
- Zingg U, "Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer", J Gastrointest Surg, 14, pp.462~469 (2010)
- Okuno T, "Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy(exploratory analysis of JCOG0303)", Int J Clin Oncol, 22, pp.1042~1049 (2017)
- Oya Y, "Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer", Oncotarget, 8, pp.103117~103128 (2017)
- Li P, "The prognostic value of pre-treatment prognostic nutritional index in esophageal squamous cell carcinoma : a meta-analysis", Medicine(Baltimore), 98, pp.e15280~ (2019)
- Tanizaki J, "Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab", J Thorac Oncol, 13, pp.97~105 (2018)
- Kurosaki T, "Glasgow Prognostic Score(GPS)and tumor response as biomarkers of nivolumab monotherapy in third-or later-line setting for advanced gastric cancer", In Vivo, 34, pp.1921~1929 (2020)
- Peng L, "Peri-pheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors", Cancer Immunol Immunother, 69, pp.1813~1822 (2020)
- Moller M, "Blood immune cell biomarkers in patient with lung cancer undergoing treatment with checkpoint blockade", J Immunother, 43, pp.57~66 (2020)
- Li M, "Change in neutrophil to lymphocyte ratio during immu-notherapy treatment is a non-linear predictor of patient outcomes in advanced cancers", J Cancer Res Clin Oncol, 145, pp.2541~2546 (2019)
- Seith F, "Is there a link between very early changes of primary and secondary lymphoid organs in (18)F-FDG-PET", MRI and treatment response to checkpoint inhibitor therapy?, 2020, pp.8, e000656~
- Yi M, "Gut microbiome modulates efficacy of immune checkpoint inhibitors", J Hematol Oncol, 11, pp.47~ (2018)
- Gong J, "The gut microbiome and response to immune checkpoint inhibitors : preclinical and clinical strategies", Clin Transl Med, 8, pp.9~ (2019)